The combination of yondelis and cisplatin is synergistic against human tumor xenografts

M. D'Incalci, T. Colombo, P. Ubezio, I. Nicoletti, R. Giavazzi, E. Erba, L. Ferrarese, D. Meco, R. Riccardi, C. Sessa, E. Cavallini, J. Jimeno, G. T. Faircloth

Research output: Contribution to journalArticle

Abstract

Yondelis™ (trabectidin, ET-743) is a marine natural product that has shown activity both in preclinical systems and in human malignancies such as soft tissue sarcoma and ovarian cancers that are resistant to previous chemotherapies. Molecular pharmacological studies indicated that Yondelis interacts with DNA and DNA repair systems in a way that is different from Cisplatin (DDP). The current study was designed to investigate the effects of the combination of Yondelis and DDP in human cancer cell lines and in xenografts derived from different tumours. The in vitro studies performed in human TE-671 rhabdomyosarcoma, Igrov-1 and 1A9 human ovarian carcinoma cell lines showed additive effects or slight synergism. Several human tumour xenografts, such as TE-671 rhabdomyosarcoma, SK-N-DX neuroblastoma, FADU head and neck, LX-1 non-small cell lung cancer (NSCLC), H-187 melanoma and SKOV HOC 8 ovarian carcinoma, showed an antitumour effect for the combination that was greater than that of each drug when given as a single agent. No consistent changes in the activity were observed if Yondelis and DDP were given 1 h apart in sequence or simultaneously. An orthotopically transplanted human ovarian cancer HOC 8 growing in the peritoneal cavity of nude mice was used that is insensitive to Yondelis alone and only moderately sensitive to DDP alone. The combination of the two drugs produced a dramatic increase of survival lasting several months. In conclusion, the combination of Yondelis and DDP is synergistic in vivo (i.e. the antitumour effect is greater than that of each drug used as a single agent at the maximum tolerated dose (MTD)) in different human tumour xenografts. The two drugs can be combined at the MTD of each drug, thus indicating there are no overlapping toxicities. These results provide a rationale for testing the combination of Yondelis and DDP in the clinic.

Original languageEnglish
Pages (from-to)1920-1926
Number of pages7
JournalEuropean Journal of Cancer
Volume39
Issue number13
DOIs
Publication statusPublished - Sep 2003

Fingerprint

trabectedin
Heterografts
Cisplatin
Neoplasms
Maximum Tolerated Dose
Pharmaceutical Preparations
Ovarian Neoplasms
Carcinoma
Cell Line
Rhabdomyosarcoma
Peritoneal Cavity
Drug Combinations
Biological Products
Neuroblastoma

Keywords

  • Cisplatin
  • Combination
  • ET-743
  • Marine natural products
  • Tumour xenografts

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

The combination of yondelis and cisplatin is synergistic against human tumor xenografts. / D'Incalci, M.; Colombo, T.; Ubezio, P.; Nicoletti, I.; Giavazzi, R.; Erba, E.; Ferrarese, L.; Meco, D.; Riccardi, R.; Sessa, C.; Cavallini, E.; Jimeno, J.; Faircloth, G. T.

In: European Journal of Cancer, Vol. 39, No. 13, 09.2003, p. 1920-1926.

Research output: Contribution to journalArticle

D'Incalci, M, Colombo, T, Ubezio, P, Nicoletti, I, Giavazzi, R, Erba, E, Ferrarese, L, Meco, D, Riccardi, R, Sessa, C, Cavallini, E, Jimeno, J & Faircloth, GT 2003, 'The combination of yondelis and cisplatin is synergistic against human tumor xenografts', European Journal of Cancer, vol. 39, no. 13, pp. 1920-1926. https://doi.org/10.1016/S0959-8049(03)00490-8
D'Incalci, M. ; Colombo, T. ; Ubezio, P. ; Nicoletti, I. ; Giavazzi, R. ; Erba, E. ; Ferrarese, L. ; Meco, D. ; Riccardi, R. ; Sessa, C. ; Cavallini, E. ; Jimeno, J. ; Faircloth, G. T. / The combination of yondelis and cisplatin is synergistic against human tumor xenografts. In: European Journal of Cancer. 2003 ; Vol. 39, No. 13. pp. 1920-1926.
@article{54949b08cc9d4d3e966cc5e63283109f,
title = "The combination of yondelis and cisplatin is synergistic against human tumor xenografts",
abstract = "Yondelis™ (trabectidin, ET-743) is a marine natural product that has shown activity both in preclinical systems and in human malignancies such as soft tissue sarcoma and ovarian cancers that are resistant to previous chemotherapies. Molecular pharmacological studies indicated that Yondelis interacts with DNA and DNA repair systems in a way that is different from Cisplatin (DDP). The current study was designed to investigate the effects of the combination of Yondelis and DDP in human cancer cell lines and in xenografts derived from different tumours. The in vitro studies performed in human TE-671 rhabdomyosarcoma, Igrov-1 and 1A9 human ovarian carcinoma cell lines showed additive effects or slight synergism. Several human tumour xenografts, such as TE-671 rhabdomyosarcoma, SK-N-DX neuroblastoma, FADU head and neck, LX-1 non-small cell lung cancer (NSCLC), H-187 melanoma and SKOV HOC 8 ovarian carcinoma, showed an antitumour effect for the combination that was greater than that of each drug when given as a single agent. No consistent changes in the activity were observed if Yondelis and DDP were given 1 h apart in sequence or simultaneously. An orthotopically transplanted human ovarian cancer HOC 8 growing in the peritoneal cavity of nude mice was used that is insensitive to Yondelis alone and only moderately sensitive to DDP alone. The combination of the two drugs produced a dramatic increase of survival lasting several months. In conclusion, the combination of Yondelis and DDP is synergistic in vivo (i.e. the antitumour effect is greater than that of each drug used as a single agent at the maximum tolerated dose (MTD)) in different human tumour xenografts. The two drugs can be combined at the MTD of each drug, thus indicating there are no overlapping toxicities. These results provide a rationale for testing the combination of Yondelis and DDP in the clinic.",
keywords = "Cisplatin, Combination, ET-743, Marine natural products, Tumour xenografts",
author = "M. D'Incalci and T. Colombo and P. Ubezio and I. Nicoletti and R. Giavazzi and E. Erba and L. Ferrarese and D. Meco and R. Riccardi and C. Sessa and E. Cavallini and J. Jimeno and Faircloth, {G. T.}",
year = "2003",
month = "9",
doi = "10.1016/S0959-8049(03)00490-8",
language = "English",
volume = "39",
pages = "1920--1926",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "13",

}

TY - JOUR

T1 - The combination of yondelis and cisplatin is synergistic against human tumor xenografts

AU - D'Incalci, M.

AU - Colombo, T.

AU - Ubezio, P.

AU - Nicoletti, I.

AU - Giavazzi, R.

AU - Erba, E.

AU - Ferrarese, L.

AU - Meco, D.

AU - Riccardi, R.

AU - Sessa, C.

AU - Cavallini, E.

AU - Jimeno, J.

AU - Faircloth, G. T.

PY - 2003/9

Y1 - 2003/9

N2 - Yondelis™ (trabectidin, ET-743) is a marine natural product that has shown activity both in preclinical systems and in human malignancies such as soft tissue sarcoma and ovarian cancers that are resistant to previous chemotherapies. Molecular pharmacological studies indicated that Yondelis interacts with DNA and DNA repair systems in a way that is different from Cisplatin (DDP). The current study was designed to investigate the effects of the combination of Yondelis and DDP in human cancer cell lines and in xenografts derived from different tumours. The in vitro studies performed in human TE-671 rhabdomyosarcoma, Igrov-1 and 1A9 human ovarian carcinoma cell lines showed additive effects or slight synergism. Several human tumour xenografts, such as TE-671 rhabdomyosarcoma, SK-N-DX neuroblastoma, FADU head and neck, LX-1 non-small cell lung cancer (NSCLC), H-187 melanoma and SKOV HOC 8 ovarian carcinoma, showed an antitumour effect for the combination that was greater than that of each drug when given as a single agent. No consistent changes in the activity were observed if Yondelis and DDP were given 1 h apart in sequence or simultaneously. An orthotopically transplanted human ovarian cancer HOC 8 growing in the peritoneal cavity of nude mice was used that is insensitive to Yondelis alone and only moderately sensitive to DDP alone. The combination of the two drugs produced a dramatic increase of survival lasting several months. In conclusion, the combination of Yondelis and DDP is synergistic in vivo (i.e. the antitumour effect is greater than that of each drug used as a single agent at the maximum tolerated dose (MTD)) in different human tumour xenografts. The two drugs can be combined at the MTD of each drug, thus indicating there are no overlapping toxicities. These results provide a rationale for testing the combination of Yondelis and DDP in the clinic.

AB - Yondelis™ (trabectidin, ET-743) is a marine natural product that has shown activity both in preclinical systems and in human malignancies such as soft tissue sarcoma and ovarian cancers that are resistant to previous chemotherapies. Molecular pharmacological studies indicated that Yondelis interacts with DNA and DNA repair systems in a way that is different from Cisplatin (DDP). The current study was designed to investigate the effects of the combination of Yondelis and DDP in human cancer cell lines and in xenografts derived from different tumours. The in vitro studies performed in human TE-671 rhabdomyosarcoma, Igrov-1 and 1A9 human ovarian carcinoma cell lines showed additive effects or slight synergism. Several human tumour xenografts, such as TE-671 rhabdomyosarcoma, SK-N-DX neuroblastoma, FADU head and neck, LX-1 non-small cell lung cancer (NSCLC), H-187 melanoma and SKOV HOC 8 ovarian carcinoma, showed an antitumour effect for the combination that was greater than that of each drug when given as a single agent. No consistent changes in the activity were observed if Yondelis and DDP were given 1 h apart in sequence or simultaneously. An orthotopically transplanted human ovarian cancer HOC 8 growing in the peritoneal cavity of nude mice was used that is insensitive to Yondelis alone and only moderately sensitive to DDP alone. The combination of the two drugs produced a dramatic increase of survival lasting several months. In conclusion, the combination of Yondelis and DDP is synergistic in vivo (i.e. the antitumour effect is greater than that of each drug used as a single agent at the maximum tolerated dose (MTD)) in different human tumour xenografts. The two drugs can be combined at the MTD of each drug, thus indicating there are no overlapping toxicities. These results provide a rationale for testing the combination of Yondelis and DDP in the clinic.

KW - Cisplatin

KW - Combination

KW - ET-743

KW - Marine natural products

KW - Tumour xenografts

UR - http://www.scopus.com/inward/record.url?scp=0142089888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142089888&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(03)00490-8

DO - 10.1016/S0959-8049(03)00490-8

M3 - Article

C2 - 12932672

AN - SCOPUS:0142089888

VL - 39

SP - 1920

EP - 1926

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 13

ER -